These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36159794)

  • 21. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.
    Shi D; Mu S; Pu F; Liu J; Zhong B; Hu B; Ni N; Wang H; Luu HH; Haydon RC; Shen L; Zhang Z; He TC; Shao Z
    Mol Oncol; 2022 Jun; 16(11):2174-2194. PubMed ID: 34894177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
    Huang X; Ke K; Jin W; Zhu Q; Zhu Q; Mei R; Zhang R; Yu S; Shou L; Sun X; Feng J; Duan T; Mou Y; Xie T; Wu Q; Sui X
    Front Immunol; 2022; 13():887048. PubMed ID: 35784334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
    Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and clinical diversity in primary central nervous system lymphoma.
    Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
    Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of angiogenesis-related subtypes, the development of a prognosis model, and features of tumor microenvironment in colon cancer.
    Wang F; Wang C; Li B; Wang G; Meng Z; Han J; Guo G; Yu B; Wang G
    Biotechnol Appl Biochem; 2024 Feb; 71(1):45-60. PubMed ID: 37881150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.
    Pei J; Gao Y; Wu A
    Front Immunol; 2024; 15():1369726. PubMed ID: 38742117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and verification of prognostic cancer subtype based on multi-omics analysis for kidney renal papillary cell carcinoma.
    Wang B; Li M; Li R
    Front Oncol; 2023; 13():1169395. PubMed ID: 37091151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.